INAB · IN8BIO, INC.

NasdaqHealthcareBiotechnology

In8bio Inc Is A Clinical-Stage Biopharmaceutical Company Focused On The Discovery, Development And Commercialization Of Gamma-Delta T Cellular Therapy Product Candidates And Gamma-Delta T Cell Engagers (Tces) For Cancer And Autoimmune Diseases. Gamma-Delta T Cells Are A Specialized Population Of T Cells That Possess Properties. It Has Conducted Two Primary Investigator-Sponsored Phase 1 Clinical Trials Evaluating Its Gamma-Delta T Cell Technologies In Cancer Patients, Which Have Both Completed Primary Enrollment. Inb-100 Is Assessing Its Deltex Allogeneic (Allo) Gamma-Delta T Cell Therapy In Adult Patients With High-Risk Leukemias Undergoing Haploidentical Stem Cell Transplantation (Hsct). It Operates In A Single Segment.

HealthcareNasdaqUSLow Float

$2.20

+59.4% latest move

Price & move as of the most recent catalyst (Dec 19) - not a live quote.

FLOAT

7.0M

FREE FLOAT %

71%

SHARES O/S

9.9M

MARKET CAP

$10.4M

EXCHANGE

Nasdaq

COUNTRY

INAB Catalyst History

Financial ResultsDec 19, 2025 · 8:01am ET

INABIN8bio, Inc. Common Stock

IN8bio Announces $40.2 Million Private Placement to Advance INB-619

Proceeds will support IND application for novel gamma-delta T cell engager.

Be early on the next INAB spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

INAB · IN8BIO, INC.

INAB Catalyst History

IN8bio Announces $40.2 Million Private Placement to Advance INB-619

IN8bio Announces $40.2 Million Private Placement to Advance INB-619

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.